Detalhe da pesquisa
1.
A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping.
Blood Cancer J;
14(1): 78, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38702349
2.
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation.
Blood Cancer J;
14(1): 82, 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38760362
3.
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Blood Cancer J;
14(1): 69, 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38649340
4.
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Am J Hematol;
2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622840
5.
MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis.
J Exp Clin Cancer Res;
43(1): 68, 2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38439082
6.
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
Br J Haematol;
204(5): 1944-1952, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38448009
7.
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Nat Commun;
15(1): 615, 2024 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38242888
8.
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience.
Blood Cancer J;
14(1): 4, 2024 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38199987
9.
Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.
Res Sq;
2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38260385
10.
Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy.
Int J Radiat Oncol Biol Phys;
119(1): 193-199, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38070713
11.
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.
Blood Adv;
8(2): 388-398, 2024 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048391
12.
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
Cancer;
130(9): 1663-1672, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38127583
13.
Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells.
Cancers (Basel);
15(23)2023 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38067393
14.
Clinical trial design change implementation for inclusive studies.
Lancet Haematol;
10(12): e953-e954, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38030317
15.
Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma.
Transplant Cell Ther;
29(1): 37.e1-37.e7, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37753818
16.
Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma.
NPJ Precis Oncol;
7(1): 95, 2023 Sep 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37723227
17.
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Lancet Haematol;
10(10): e825-e837, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708911
18.
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
Transplant Cell Ther;
29(12): 757-762, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37673125
19.
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
N Engl J Med;
389(11): 1009-1022, 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646702
20.
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience.
Am J Hematol;
98(10): 1571-1578, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37461327